114828-90-9

Basic information

• Product Name: (E)-4-Hydroxy-N-desmethyl Tamoxifen
• Synonyms: (E)-4-Hydroxy-N-desmethyl Tamoxifen
• CAS NO: 114828-90-9
• Molecular Formula: C₂₅H₂₇NO₂
• Molecular Weight: 373.48738
• Product Categories: Aromatics;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals;Aromatics, Metabolites & Impurities, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 114828-90-9.mol

Chemical Properties

• Melting Point: 154-156°C
• Appearance: /
• Storage Temp.: -20°C Freezer
• CAS DataBase Reference: (E)-4-Hydroxy-N-desmethyl Tamoxifen(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-4-Hydroxy-N-desmethyl Tamoxifen(114828-90-9)
• EPA Substance Registry System: (E)-4-Hydroxy-N-desmethyl Tamoxifen(114828-90-9)

Safety Data

• Hazardous Substances Data: 114828-90-9(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Upstream product

• 74-89-5 methylamine 
• 147323-02-2 E/Z-1-[4-(2-bromoethoxy)phenyl]-1-(4-hydroxyphenyl)-2-phenylbutene 
• 1231730-32-7 (4-hydroxyphenyl)(4-(2-(methylamino)ethoxy)phenyl)methanone hydrochloride 
• 93-55-0 1-phenyl-propan-1-one 
• 119757-57-2 (E,Z)-1-<4-(2-chloroethoxy)phenyl>-1-(4-hydroxyphenyl)-2-phenyl-1-butene 
• 1189368-86-2 C₂₄H₂₂O₃ 
• 110025-28-0 (E/Z)-4-[1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenyl-1-buten-1-yl]-phenol 
• 173163-13-8 4-<2-(N,N-dimethylamino)ethoxy>-4'-hydroxybenzophenone 
• 1231819-50-3 (4-hydroxyphenyl)(4-(2-(methylamino)ethoxy)phenyl)methanone 

Downstream Products

• 1189368-63-5 N-Boc-(E)-endoxifen 
• 1189368-62-4 (S,Z)-4-(1-(4-(2-(tert-butoxycarbonyl(methyl)amino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenyl 2-(tert-butoxycarbonylamino)-3-methylbutanoate 

Relevant articles and documents

TOPICAL COMPOSITIONS AND METHODS FOR TREATMENT

The present disclosure provides novel topical compositions comprising endoxifen and salts and solvates thereof and methods for making the compositions. Certain compounds have been combined to make a stable topical compositions comprising endoxifen. The pr

Substituted triphenyl butenes

The present invention is directed to compounds, compositions thereof, and the use of the compounds and compositions for the treatment and prevention of breast cancer. In one embodiment, the present invention relates to the use of a substituted triphenyl b

A convenient synthesis of (Z)-4-hydroxy-N-desmethyltamoxifen (endoxifen)

A mixture of the (Z)- and (E)-isomers of 4-hydroxy-N-desmethyltamoxifen was conveniently prepared in four steps. These geometrical isomers were then neatly separated by semi-preparative Reverse Phase High Performance Liquid Chromatography (RP-HPLC) using specified conditions. Additionally, the isolated E-isomer could be equilibrated in aqueous strong acid in acetonitrile or trifluoroacetic acid/dichloromethane to give a clean 1:1 mixture of Z/E isomers that was re-subjected to HPLC separation. In this way, most of the undesired (E)-isomer could be readily converted to the desired (Z)-isomer providing quick access to over 200 mg quantities of pure endoxifen (Z-isomer), a potent antiestrogenic metabolite of tamoxifen traditionally used in breast cancer treatment.

Endoxifen is a new potent inhibitor of PKC: A potential therapeutic agent for bipolar disorder

Protein kinase C (PKC) plays a major role in regulation of both pre and postsynaptic neurotransmission. Excessive activation of PKC results in symptoms related to bipolar disorder. Tamoxifen, a widely used breast cancer drug is known to inhibit PKC and demonstrate antimanic properties in human. We describe herein the synthesis of endoxifen, a tamoxifen active metabolite and compared its PKC inhibitory activity with that of tamoxifen. Endoxifen exhibited fourfold higher potency compared to tamoxifen.

TARGETED DRUG-FORMALDEHYDE CONJUGATES AND METHODS OF MAKING AND USING THE SAME

The invention provides a prodrug platform technology for improving the therapeutic value of a variety of parent drug compounds by altering and improving drug characteristics such as aqueous solubility, hydrolytic stability, therapeutic index, toxicity profile, pharmacokinetics and selectivity while allowing the potential for synthetic elaboration. The prodrug platform is particularly well suited for targeting therapeutic drugs, including anti-tumor drugs and antibiotics, to specific receptors on target cells (e.g., cancer cells and bacteria). The platform is a technology for providing an improved, preactivated form of a therapeutic drug, and for optionally targeting such drug to target cells or biological molecules. The invention is broadly applicable to many different therapeutic drugs, as well as to a variety of diseases and conditions, including a variety of forms of cancer and bacterial infections.

Triphenylethylenes, process for their production, pharmaceutical preparations that contain these triphenylethylenes as well as their use for the production of pharmaceutical agents

This invention describes the new triphenylethylenes of general formula I STR1 in which n means an integer from 1 to 10, R' means a sulfur-containing organic radical, R" means a hydrogen atom, an iodine atom or a hydroxy groups, E means a hydrogen atom, G